| Barchart Demo Center |
$0,66
+0,01 (+1,54%)
en date du oct 11, 2019
en date du oct 11, 2019
| Profil | |
|---|---|
| Symbole | KMPH |
| Marché | NASDAQ |
| Informations de contact |
1180 Celebration Boulevard Suite 103 Celebration, FL USA P: 321-939-3416 |
| Président | Travis C. Mickle |
| Bénéfices à vue d'oeuil | ||||
|---|---|---|---|---|
| Bénéfices | 06/30/19 -0.33 |
03/31/19 -0.46 |
12/31/18 0.21 |
09/30/18 -0.94 |
| Ratio prix/bénéfices | N/A | |||
| Croissance du BPA | 53,82 | |||
| Most Recent Earnings ($) | -0,33 | |||
| Annual EPS ($) | -1,93 | |||
| Résumé business | |
|---|---|
| KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE United States. | |
| Industrie/Secteur | Information not available. |